TGFB1 and idiopathic interstitial pneumonia: Moreover, we demonstrated that GSK3008348 could inhibit pSmad2 in human diseased samples using PCLS from IPF patients confirming that GSK3008348 can inhibit TGFβ activation pathways both in human fibrotic tissue as well as a murine model of lung fibrosis.